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Purpose: Pain in terminal cancer patients may be refractory to systemic analge-
sics or associated with adverse drug reactions to analgesics. Epidural analgesia has 
been effectively used in such patients for pain control. However, this method does 
not provide pain relief to all patients. The efficacy and complications of continu-
ous epidural analgesia were evaluated for expanding efficacy in terminal cancer 
patients. Materials and Methods: The charts of patients who received epidural 
analgesia for over 5 years for the control of terminal cancer pain were reviewed 
retrospectively. Results: Ninety-six patients received 127 epidural catheters. The 
mean duration for epidural catheterization was 31.5±55.6 (5-509) days. The dose 
of epidural morphine increased by 3.5% per day. The efficacy of epidural analge-
sia at 2 weeks follow up revealed improved pain control (n=56), as the morphine 
equivalent drug dose dropped from 213.4 mg/day to 94.1 mg/day (p<0.05) at 2 
weeks follow up. Accordingly, after 2 weeks institution of epidural analgesia, there 
was a significant reduction in the proportion of patients with severe pain, from 
78.1% to 19.6% (p<0.05). Conclusion: Epidural analgesia was an effective pain 
control method in patients with terminal cancer pain, however, a systematized al-
gorithm for the control of cancer-related pain in needed.
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INTRODUCTION
Cancer has been the most common cause of death in Korea since 1983. The num-
ber of cancer patients was 153237 in 2006 and 161920 in 2007, with an increased 
frequency of 5.1% and 11.0%, respectively, in comparison to 2005. Alarmingly, 
the incidence and prevalence of cancer continues to increase. Assuming a lifespan 
of 76 years in men and 83 years in women, one out of three men and one out of 
four women are predicted to develop cancer during their lifetime in Korea.1 
Seventy-five to 80% of terminal cancer patients complain of cancer-related pain.2 
The World Health Organization and National Cancer Care Network presented algo-
rithms for cancer pain control.3,4 These guidelines have been validated in clinical 
practice and were shown to provide effective analgesia in 70-90% of patients.3,5 Yeon Soo Jeon, et al.
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The mean daily doses of epidural morphine at the start 
and termination were also evaluated. The dose escalations 
of the epidural morphine, the ratio of the maximum dose to 
the minimum start dose, were evaluated for the daily in-
crease percentage of epidural morphine.
As the survival period of more than 2 weeks had the high-
est number of patients (n=56), the efficacy of pain control 
was indirectly evaluated according to changes in intrave-
nous morphine equivalent drug dose (MEDD) and the de-
gree of pain at pre-epidural and 2 weeks follow up. The de-
gree of pain was defined as none to mild, moderate, and 
severe. Complications were also evaluated.
Statistical analysis
The results are presented as the mean±SD or incidence 
(percentage). Paired samples t-test was used to examine the 
change in MEDD, at pre-epidural and 2 weeks follow up. 
Statistical analyses were performed using SPSS software 
version 13.0. p-value<0.05 was considered significantly 
significant.
This study was approved by the Institutional Review 
Board of - St. Vincent’s Hospital, College of Medicine, The 




Two hundred and twenty-eight hospitalized cancer patients 
with pain were referred to the pain clinic due to severe ad-
verse drug reactions or ineffective pain control in spite of 
opioid administration. One hundred and thirty-two (58%) 
patients had at least one EA performed. Ninety-six (42%) 
patients underwent continuous EA.
Patient characteristics including age, gender, primary 
cancer, pain location, type of pain, and pre-epidural failure 
are shown in Table 1. Ninety-six patients were treated using 
127 catheters. The catheter characteristics are shown in Ta-
ble 2. Positions of the catheter tips of 73 catheters were 
confirmed by plain radiographs. Forty-eight (65.7%) cathe-
ters were located at the target site level or within 3 cm of 
the target site, while 25 (34.2%) catheters were inappropri-
ately placed outside the target site.
The mean epidural doses of morphine at the start and ter-
mination were 21.24±20.6 mg and 56.7±61.4 mg, respec-
tively. The mean dose escalation of epidural morphine over 
time was 2.8±2.3. Mean duration of epidural catheterization 
However, it is very difficult to control cancer-related pain 
refractory to medical management.3 For these patients, con-
tinuous epidural analgesia (EA), intrathecal analgesia 
(ITA), and intracerebroventricular analgesia (ICVA) have 
been very effective.6-10 Therefore, EA or ITA is considered 
the fourth ladder of treatment.3 
ITA and ICVA have many advantages. However, they ne-
cessitate more aggressive surgical procedures and are very 
expensive. And the risk of spinal infection, confusion, and 
sedation are also high.10
EA is easy to perform and is effective for patients with a 
predicted survival less than three months.11 The cost is also 
covered for 95% of cancer patients by national health insur-
ance in Korea. For these reasons, the EA is preferred and is 
used for control of cancer-related pain in Korea. Nonethe-
less, the efficacy of EA varies among patients.
The purpose of this study was to evaluate the efficacy 
and complications of continuous epidural analgesia in order 
to improve its efficacy for control of cancer-related pain.
MATERIALS AND METHODS
　　　
Ninety-six terminal cancer patients were referred to the 
pain clinic for pain control and were administered EA from 
2005 to 2009. A retrospective review of their medical re-
cords was performed. 
A coiled 18G epidural catheter (Arrow, Arrow Interna-
tional Inc., Reading, PA, USA) was used for catheteriza-
tion, which tunneled into the nearby trunk. Morphine, bupi-
vacaine, and ketamine were used for most patients as the 
initial epidural drugs. After the daily total opioid dose was 
converted into an intravenous morphine equivalent dose, 
epidural morphine was injected at 1/4-1/6 of the intrave-
nous morphine dose.
Bupivacaine 12.5-25 mg/day and ketamine 10-20 mg/
day were injected at 2 mL/h according to the patient’s pain 
severity, cancer progress, pain location, and type of pain. 
Adjuvant analgesics were used including antiepileptic drugs, 
antidepressants, anti-inflammatory drugs, and, in some cas-
es, steroids.
Patient characteristics including age, gender, primary can-
cer, pain location, pain type, and causes of pre-epidural fail-
ure were evaluated. In addition, the mean duration of epi-
dural catheterization, the level of the EA, the position of the 
tip of the epidural catheter, the number of reinsertions, and 
the catheter course were also evaluated.Epidural Analgesia in Cancer Pain
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due to the draining of interstitial fluid through the puncture 
site caused by generalized edema. Presenting drug related 
complications included respiratory depression to a rate of 8 
breath/min in 1 patient, motor block in 1 patient, hypoten-
sion in 1 patient, and sensory deficits in 2 patients. All of 
these problems were resolved with dose reduction. Consti-
pation occurred in most patients, and urinary retention was 
resolved by symptomatic treatment.
DISCUSSION
The results of this study showed that continuous epidural 
analgesia significantly decreased the MEDD of morphine 
in terminal cancer patients and reduced the proportion of 
patients with severe pain. 
Prior studies previously reported that the continuous EA 
was effective in 50-90% of patients.7,9,12 Ballantyne and Car-
wood10 reported EA showed excellent pain relief in 72% of 
patients with terminal cancer-related pain by performing a 
meta-analysis of 31 studies. Burton, et al.13 reported there 
was a significant reduction in the proportion of patients with 
severe pain from 86% to 17% after neuroaxial analgesia. In 
our study, EA was deemed effective in 80.4% of patients. 
In our study, EA was effective immediately after institu-
tion in the majority of patients however, approximately 30% 
of patients showed decreased efficacy over time. Mer-
cadante14 suggested that tumor progression, psychological 
factors, development of pseudotolerance caused by dural 
thickening, impedance of transdural diffusion, epidural me-
tastasis with the invasion of nerve roots, and reactive fibrosis 
were some of the potential causes of reduced effectiveness 
was 31.5±55.6 days, and the dose of epidural morphine in-
creased by 5.3% per day.
The efficacy of EA at 2 weeks follow up revealed im-
proved pain control (n=56), as MEDD dropped from 213.4± 
221.7 (10-1480) mg/day to 94.1±145.0 (30-680) mg/day at 
2 weeks follow up (p<0.05). After 2 weeks institution of 
EA, there was a significant reduction in the proportion of 
patients with severe pain, from 78.1% to 19.6% (p<0.05).
Catheter related complications were as follows: mild, 
such as spontaneous removal or removal by mistake in 15 
patients (15.6%). And moderate complications, including 
infection, occlusion, oozing, and formation of fibrous 
sheath occurred in 14 patients (14.6%). Infection occurred 
at the entrance and tunnel sites, but all infections were con-
trolled by antibiotics and/or catheter removal. Bloody dis-
charge occurred in 2 patients with a long-term catheter. Se-
vere complications such as epidural abscess or hematoma 
did not occur. Oozing occurred in three patients, perhaps 
Table 1. Patient Characteristics 
Total (n=96) 
Age (yrs)
    40<   9 (9.4%)
    41-59 35 (36.5%)
    60≤ 52 (54.2%)
Sex
    Male 54 (56.2%)
    Female 42 (43.8%)
Primary cancer
    Lung cancer 18 (18.8%)
    UGI cancer 23 (24.0%)
    Hepatobiliary cancer 10 (10.4%)
    Pancreatic cancer 15 (15.6%)
    Rectosigmoidal cancer 13 (13.5%)
    Urogenital cancer   7 (7.3%)
    Etc. 10 (10.4%)
Pain location
    Head, neck and upper extremity   8 (8.3%)
    Chest, abdomen and back, sacral and 
      lower extremity 88 (91.6%)
Pain type
    Somatic 10 (10.4%)
    Visceral 57 (59.4%)
    Neuropathic   2 (2.1%)
    Mixed 27 (28.1%)
Pre-epidural failure
    Inappropriate pain control 75 (78.1%)
    Intolerable side effect 21 (21.9%)
UGI, upper gastrointestinal.  
Values are expressed as the incidence (percentages).
Table 2. Catheter Characteristics
Total (n=96)





    Cervical    6 (6.3%)
    Thoracic 61 (63.5%)
    Lumbosacral 29 (30.2%)
Number of catheterizations
    1 73 (76.1%)
    2  15 (15.6%)
    3   8 (8.3%)
Catheter maintenance
    Catheter in place until the time of death 73 (76.0%)
    Change to intravenous morphine  23 (24.0%)
Values are expressed as the incidence (percentages).Yeon Soo Jeon, et al.
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ever, it is not available in Korea. Urinary retention was also 
severe if the catheter tip was located in the lower lumbar epi-
dural space. This was treated by symptomatic therapy.
The optimal time for commencing EA remains unclear. 
Often, spinal opioid treatment was initiated before optimal 
systemic opioid administration was achieved.14 However, in-
discriminate use of spinal opioids should be discouraged.23 In 
our study, seven patients could have been adequately con-
trolled pain by appropriate systemic analgesics alone. Cur-
rently, we consider EA in patients with intolerable side ef-
fects despite systemic analgesics or in patients with refractory 
pain despite receiving morphine 100 mg/day intravenously. 
The limitations of this study were as follows: first, this 
was a retrospective study. Second, we did not use an objec-
tive pain score. This trend was shown in most papers con-
cerning neuroaxial therapy for terminal cancer pain.10 Al-
though it is possible to measure pain scores during the early 
period of disease, it becomes difficult to measure as the dis-
ease progresses. Additionally, other limitations include the 
absence of a comparison group, bias with patient reporting 
of symptoms and analgesic intake, as well as inaccurate 
data in the medical records. 
In conclusion, in terminal cancer patients with severe 
drug side effects or refractory pain, epidural analgesia was 
an effective pain control method, however, a systematized 
algorithm for improving the efficacy of epidural analgesia 
is needed.  
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